Youssef et al. (32, 33) performed two consecutive Cochrane metaanalyses to assess the safety and efficacy of subcutaneous rhCG and high-dose rLH compared with intramuscular uhCG for inducing final oocyte maturation triggering in IVF and ICSI cycles and they concluded that equivalent pregnancy rates and OHSS incidences were found between rhCG or rhLH and uhCG when used for final follicular maturation in IVF. The gene discussed is RHCG; the disease is ovarian hyperstimulation syndrome.